"The Stone Pharmaceutical Group and Cipla have entered into an exclusive licensing agreement for the commercialization of Ilicinol liposomal injection in the United States."

Shiyao Group announced that the group has entered into an exclusive license agreement with Cipla USA, Inc. for the commercialization of the group's Eritoran Zinc Liposomal Injection in the United States. According to the terms of the agreement, the group has agreed to grant Cipla an exclusive license to commercialize the product in the region. The group will receive an upfront payment of $15 million, as well as potential milestone payments of up to $25 million for first commercial sales and regulatory milestones and up to $1.025 billion in potential additional commercial sales milestones, as well as double-digit tiered sales royalties based on annual net sales of the product in the region.